Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 6NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Melanoma 1Breast Neoplasms 1

Interventions

pembrolizumab 284Carboplatin 216Cisplatin 148Paclitaxel 145Gemcitabine 145Bevacizumab 117Pemetrexed 114Docetaxel 103Oxaliplatin 79Cyclophosphamide 79Dexamethasone 78durvalumab 77atezolizumab 77Fluorouracil 77Nivolumab 75130-nm albumin-bound paclitaxel 71Fulvestrant 68Capecitabine 64Injections 63Cetuximab 63Leucovorin 60Rituximab 56fludarabine 52Lenalidomide 49Prednisone 46venetoclax 43Irinotecan 43Letrozole 40enzalutamide 39tislelizumab 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Eflornithine × 90 days × Clear all
NCT07287917 2026-05-12

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Aminex Therapeutics, Inc.

Phase 1/2 Recruiting
92 enrolled
BreastDermatologic

Breast Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡